SCYNERGIA
A Phase 2 Trial - Combination Therapy of Ibrexafungerp (SCY-078) with Voriconazole in Patients with Invasive Pulmonary Aspergillosis
Learn more hereOngoing Clinical Trials
FURI
Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp (SCY-078) in Patients with Refractory or Intolerant Fungal Diseases
Learn more here
CARES
Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp (SCY-078) in Patients with Candidiasis Caused by Candida Auris
Learn more here
CANDLE
Ibrexafungerp for Recurrent Vulvovaginal Candidiasis (RVVC)
SCY-0789-304 is a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC). Enrollment is complete.
ClinicalTrials.gov Identifier: NCT04029116
Learn more here
VANQUISH
Phase 3b, open-label, multicenter study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a treatment for complicated vulvovaginal candidiasis (VVC) in patients who have failed treatment with fluconazole, based on mycological and clinical outcomes.
Learn more hereInterested In Our Clinical Trials?
If you have any questions, please contact us at ClinicalTrials@SCYNEXIS.com.